- Home
- RLYB vs GDTC Comparison
RLYB vs GDTC Comparison
Compare RLYB & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- GDTC
- Stock Information
- Founded
- RLYB 2018
- GDTC 2018
- Country
- RLYB United States
- GDTC Singapore
- Employees
- RLYB N/A
- GDTC N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- RLYB Health Care
- GDTC Health Care
- Exchange
- RLYB Nasdaq
- GDTC Nasdaq
- Market Cap
- RLYB 25.0M
- GDTC 29.4M
- IPO Year
- RLYB 2021
- GDTC 2023
- Fundamental
- Price
- RLYB $0.25
- GDTC $2.46
- Analyst Decision
- RLYB Hold
- GDTC Buy
- Analyst Count
- RLYB 5
- GDTC 1
- Target Price
- RLYB $11.50
- GDTC $5.00
- AVG Volume (30 Days)
- RLYB 194.2K
- GDTC 32.8K
- Earning Date
- RLYB 05-08-2025
- GDTC 01-01-0001
- Dividend Yield
- RLYB N/A
- GDTC N/A
- EPS Growth
- RLYB N/A
- GDTC N/A
- EPS
- RLYB N/A
- GDTC N/A
- Revenue
- RLYB $636,000.00
- GDTC $330,254.00
- Revenue This Year
- RLYB N/A
- GDTC $14.71
- Revenue Next Year
- RLYB N/A
- GDTC N/A
- P/E Ratio
- RLYB N/A
- GDTC N/A
- Revenue Growth
- RLYB N/A
- GDTC N/A
- 52 Week Low
- RLYB $0.22
- GDTC $1.20
- 52 Week High
- RLYB $2.00
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- RLYB 22.80
- GDTC 49.89
- Support Level
- RLYB $0.24
- GDTC $2.26
- Resistance Level
- RLYB $0.28
- GDTC $2.53
- Average True Range (ATR)
- RLYB 0.06
- GDTC 0.25
- MACD
- RLYB -0.02
- GDTC 0.01
- Stochastic Oscillator
- RLYB 6.12
- GDTC 55.38
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.